Human cervical cancer is caused by high-risk types of human papillomavirus (HPV) such as HPV16 and HPV18, which possess the E6 and E7 oncogenes, whose concurrent expression is a prerequisite for cancer development and maintaining malignant phenotypes. Silencing these oncogenes is considered to be applicable in molecular therapies of human cervical cancer. However, it remains to be determined whether E6, E7, or both should be silenced to obtain most efficient antitumor activity by an HPV smallinterfering RNA (siRNA). Herein, we report two types of siRNAs targeting HPV18 E6, that exerted a negative growth effect on HPV18-positive cervical cancer cells (HeLa and SW756), in part, inducing cell death. One siRNA (Ex-18E6), designed to target both E6-E7 mRNA and its splicing variant, E6*I-E7 mRNA, efficiently knocked down both E6 and E7 expression. The other (Sp-18E6), designed to specifically target E6-E7 mRNA but not E6*I-E7 mRNA, suppressed E6 to a similar level as Ex-18E6; however, it less efficiently inhibited E7 as compared to Ex-18E6. Although both siRNAs induced cell death, Sp-18E6 siRNA induced more prominent cell death than Ex-18E6. Our results suggest that E6-specific suppression may induce more potent anticancer activity than simultaneous E6 and E7 suppression, and that E6-specific targeting is a promising strategy for siRNA-based therapy for HPVpositive cervical cancer.
Introduction
A strong association between specific human papillomavirus (HPV) types and genital cancer has been well established 1 and high-risk types of HPV including types 16 and 18 have been identified in nearly two-thirds of all cervical cancer patients worldwide. 2, 3 These HPVs encode the E6 and E7 oncoproteins, which are essential for malignant transformation as well as maintenance of the malignant phenotype of cervical cancer. 4, 5 The transforming properties of the E6 and E7 proteins are due to their capacity to bind to and inactivate the p53 tumor suppressor protein and members of the retinoblastoma (Rb) tumor suppressor protein family, respectively, which play pivotal roles in the cell cycle checkpoint. 6 Therefore, these viral oncogenes are considered to be the ideal targets for development of novel therapeutic strategies for HPVpositive cervical cancers.
Small-interfering RNAs (siRNAs) have been recently shown to be the most powerful tools that can silence gene expression by degrading mRNA in a sequence-specific manner. Extensive research on the development of therapeutic siRNA has been carried out since these small RNA molecules were shown to possess RNAi activity in mammalian cells in 2001. 7, 8 Further, recent in vitro and in vivo experiments have successfully demonstrated a potential applications of siRNAs for treatment of human cancers. [9] [10] [11] [12] We and others have reported that downregulation of HPV16 E6 and E7 expression by E6 siRNA led to retarded growth of HPV16-positive cervical cancer cells, 13, 14 and proposed that siRNA-induced E6 and E7 silencing has a major therapeutic potential. E6 is encoded by full-length E6-E7 cistronic mRNA, whereas E7 is encoded by E6-E7 mRNA as well as its splicing variant, E6*I-E7 mRNA. Therefore, E6-E7 mRNA-specific siRNA (E6 monospecific siRNA) can preferentially downregulate E6, whereas siRNA containing a common sequence between E6-E7 mRNA and E6*I-E7 mRNA can knock down both E6 and E7 (E6E7-specific siRNA). 15, 16 Recently, Butz et al. 17 reported that E6 monospecific siRNA led to apoptotic cell death of HPV18-positive cancer cells. On the other hand, simultaneous suppression of E6 and E7 by E6E7-specific siRNA caused cellular senescence in HPV18-positive cancer cells. 18 These observations suggest that E6 monospecific siRNA might be superior for human HPV-positive cancer therapy to E6E7-specific siRNA. In the present study, we identified an E6 monospecific siRNA that showed greater levels of potent activities of growth suppression and cell death induction as compared with an E6E7-specific siRNA. Our results may be useful for developing siRNA therapeutics strategies for cervical cancer.
Materials and methods
Cell lines and plasmid transfection HPV18 genome positive cell lines (HeLa, SW756) were purchased from American Type Culture Collection (ATCC, Rockville, MD), and COS-1 cells were provided by Japanese Collection of Research Biosources (JCRB). Cells were maintained in DMEM containing 10% FBS at 371C and 5% CO 2 . At 16-24 h before transfection, COS-1 cells were seeded at 8 Â 10 4 cells/well in 24-well plates, and then cotransfected with 500 ng of expression plasmids and 60 pmol of each siRNA using Lipofectamine 2000 transfection reagent (Invitrogen, Carlsbad, CA) as instructed by the manufacturer. After 24 h of incubation, the cells were washed once with Dulbecco's PBS and directly dissolved in 100 ml of SDS gel loading buffer (50 mM Tris-HCl at pH 6.8, 2% SDS, 0.1% bromophenol blue, 10% glycerol), and then heated at 951C for 5 min before being analyzed by immunoblotting.
siRNA and transfection
The target sequence of E6 siRNA was selected between 50 and 150 bp downstream of the start codon with a GC content of about 50%. The sequence was submitted to a BLAST search against the human genome sequence to ensure that no gene of the human genome was targeted. RNA duplexes (19-base) with a 2 nt deoxythymidine overhang at the 3 0 end were synthesized and purified by HPLC (Japan Bio Services Co. Ltd, Saitama, Japan; Dharmacon Research Inc., Lafayette, CO). For annealing of the siRNAs, 20 mM of sense and antisense strands was incubated in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate) for 1 min at 901C, followed by 1 h for 371C.
The siRNAs used in the present study were as follows: lamin A/C siRNA sense strand, 5 0 -GUAAUGCUUGCUUAUAUACdTdT-3 0 . To obtain the maximal RNAi effects, siRNA transfection 19 was repeated at 48 h after the first transfection. 14 At 1 day prior to transfection, HeLa and SW756 cells were transferred to 24-well plates at 5 and 7 Â 10 4 cells/well, respectively. A 3 ml portion of Oligofectamine (Invitrogen) and 12 ml of OPTI-MEM I medium (Life Technology) were mixed and incubated at room temperature for 5 min. During the incubation, 3 ml of siRNA (20 mM) was mixed with 50 ml of OPTI-MEM I medium. The two mixtures were then combined and incubated for 20 min at room temperature. Following addition of 32 ml of OPTI MEM I medium, the entire mixture was added to cells that had been washed with PBS and immersed in 500 ml of serumfree or tissue culture medium, resulting in a final concentration of 100 nM of siRNA. At 4 h after transfection, 60 ml of FBS was added to the culture when transfection was carried out under serum-free condition. After 24 h incubation, cells were trypsinized and seeded in 24-well plates at the same population. After 24 h cultivation, the second siRNA transfection was performed in the same manner as in the first.
Plasmid construction
A coding region of HPV18 E6 was obtained by polymerase chain reaction (PCR) amplification using HPV18/pBR322 (a gift of Dr H Sakai, Institute for Virus Research, Kyoto University, Kyoto, Japan) and sense and antisense E6 primers containing NheI and XbaI sites at the 5 0 end and then subcloned into pCR II and sequenced. The cloned E6 fragment was isolated by digestion with NheI and XbaI and then ligated at the XbaI site of the pcDNA3-FLAG plasmid. The resultant plasmids were designated FLAG-18E6/pcDNA3. PCR primers used for construction of the FLAG-tagged expression plasmid were as follows: 18E6-s, 5
0 -GTAGCTAGCATGGCGCG CTTTGAGGATCC-3 0 ; and 18E6-as, 5 0 -GCTAGCTTAT ACTTGTGTTTCTCTGC-3 0 (NheI and XbaI sites are underlined).
Analysis of in vitro cell growth Cell viability was examined using a colorimetric assay with WST-8 (Cell Counting Kit 8, Dojin Laboratories, Kumamoto, Japan) according to the manufacturer's instructions. For the colony forming assay, cells were retransfected with siRNA, incubated for 48 h, trypsinized, and then suspended in 0.3% agar noble (Difco Laboratories, Detroit, MI) containing DMEM and 10% FCS at a density of 500 cells/ml. Next, 1.2 ml of the cell suspension was placed over 0.8 ml of 0.5% agar noble containing DMEM and 10% FCS in 12-well plates. After plating, 1 ml of DMEM containing 10% FBS was added to the soft agar cultures and replenished every 3 days.
Cells were allowed to grow for 12-14 days and colonies consisting of more than 50 cells were counted. All assays were performed in triplicate and repeated three times.
Immunoblotting
Cells at 1-2 Â 10 5 were washed with Dulbecco's PBS once, directly dissolved in 50 ml of SDS gel loading buffer, and incubated for 5 min at 951C. A 15 ml portion of each sample was separated on a polyacrylamide gel containing 0.1% SDS. Immunoblot analysis was performed as described previously. 20 Anti-FLAG monoclonal antibody (M2) was purchased from Sigma-Aldrich Corporate (St Louis, MO). Anti-p53 (Bp53-12), anti-HPV18 E7 (N-19), anti-lamin A/C (346), and a-vimentin monoclonal antibodies were obtained from Santa Cruz Biotechnology Incorporation (Santa Cruz, CA).
Reverse transcription-polymerase chain reaction DNA-free cytoplasmic RNA was obtained from cultured cells using an RNeasy Kit (Qiagen, GmbH, Hilden, Germany) and an RNase-Free DNase Set (Qiagen), according to the manufacturer's instructions. Singlestranded cDNAs were synthesized from 500 ng of RNA using a Reverse Transcription System (Promega, Madison, WI). cDNA samples were serially diluted (1:5, 1:25), and subjected to PCR amplification with forward and reverse primers specific to HPV18 E6, HPV18 E7, or bactin using ExTaq polymerase (Takara, Kyoto, Japan). As negative controls, RNA samples without reverse transcription were used. PCR analyses of E6 and E7 cDNA fragments were performed under the following conditions: denaturation at 941C for 5 min, followed by 24-26 PCR cycles (denaturation at 941C for 30 s, primer annealing for E6 at 611C for 30 s, for E7 at 551C for 30 s, primer extension at 721C for 30 s). b-actin cDNA was detected by denaturation at 941C for 5 min, followed by 20 PCR cycles (denaturation at 941C for 30 s, primer annealing at 551C for 30 s, primer extension at 721C for 30 s). Amplified products were separated on 2.5% agarose gels and then stained with SYBR GOLD (Molecular Probes, Eugene, OR). The gels were photographed using a 300 nm ultraviolet transilluminator and a Syber Green/ Gold photographic filter. Intensities of the E6 and E7 bands from E6 siRNA-treated cells (1:1) were quantified using Intelligent Quantifier software (Bio Image, Ann Arbor, MI) and normalized to those of the b-actin band. Relative E6 and E7 mRNA levels were calculated by regression analysis by comparing with those of serially diluted samples from mock-transfected cells as standards. PCR primers used for detection of E6, E7, and b-actin cDNA were as follows:
0 -CTCACCATGGATGATGATAT-3 0 ; and b-actin-as,
Flow cytometry Dead cells were quantified by annexin V-FITC and propidium iodide double staining using a staining kit from PharMingen (San Diego, CA), according to the manufacturer's instructions, and analyzed by flow cytometry. The log of annexin V-FITC and propidium iodide fluorescence was displayed on the X-and Y-axis of the cytogram, respectively. Annexin V-positive cells plotted in the lower and upper right quadrants were evaluated as dead cells.
Results

HPV18 E6 siRNA inhibits transient expression of E6 oncogene plasmid
We chose two siRNAs that targeted HPV18 E6 for growth inhibition of HPV18-related cancer cells. The first (Ex-18E6) was selected from the common region of E6-E7 mRNA, and its splicing variant E6*I-E7 mRNA, which was expected to knock down both species of mRNA to a similar extent, resulting in a downregulation of both E6 and E7 (E6E7-specific siRNA). The second (Sp-18E6), which contained a borderline sequence of the E6* splicing donor site and intron, was expected to downregulate E6-E7 mRNA more efficiently than E6*I-E7 mRNA, causing a strong suppression of E6 and lesser suppression of E7 (E6 monospecific). Most HPV18-related cancer cells express E6 at a low level and lack of a high-affinity antibody against E6 makes it difficult to evaluate the effect of a siRNA on E6 expression by immunoblotting. To surmount this problem, we generated a FLAG-tagged HPV18 E6 expression plasmid. As shown in Figure 1 , immunoblot analysis of COS-1 cells transfected with FLAG-18E6 using the We next tested the effects of these E6 siRNAs on the expression of endogenous E6 and E7 mRNA in HeLa cells using a semiquantitative reverse transcription (RT)-PCR method. HeLa cells were transfected with buffer alone, control siRNA, Sp-18E6 siRNA, or Ex-18E6 siRNA, and then cultured for 3 days, after which cytoplasmic RNA was extracted. cDNA was synthesized from the cytoplasmic RNA, serially diluted, and then subjected to PCR amplification with E6-or E7-specific primers. Sp-18E6 siRNA decreased the levels of E6 and E7 to 3 and 20%, respectively. Ex-18E6 siRNA decreased the levels of both to 4% (Figure 2 ). Similar results were obtained for SW756 cells (data not shown).
Effects of E6 siRNAs on the expression of p53 and E7 proteins
We found that E6 siRNAs downregulated levels of mRNA coding E6 and E7 in HPV18-positive cells. Since endogenous E6 protein expression is undetectable by immunoblotting, we confirmed the knockdown of E6 protein by assessing the level of p53, which is degraded by E6 through the ubiquitin-proteasome process. 21, 22 Immunoblot analysis detected accumulation of p53 in Sp-18E6 siRNA-treated HeLa cells, whereas p53 was undetectable in buffer and control siRNA-transfected cells (Figure 3) . Interestingly, Ex-18E6 did not increase p53 in HeLa cells (Figure 3) , even though Ex-18E6 siRNA downregulated E6 mRNA to the same extent as Sp-18E6 (Figure 2) . In SW756 cells, Sp-18E6 siRNA increased p53 levels slightly higher than Ex-18E6 (Figure 3) . The effect of Ex-18E6 siRNA on E7 protein level was examined by immunoblotting and it was found to be more potent in the suppression of E7 protein level than Sp-18E6 siRNA in HeLa cells, which was comparable to the RT-PCR results ( Figure 2) . Similarly, Ex-18E6 siRNA resulted in a 10-fold decrease in the E7 level as compared with control siRNA, while Sp-18E6 caused a 2.5-fold decrease in the E7 level in SW756 cells.
Effects of E6 siRNA on the growth of HPV18-related cancer cells
HeLa and SW756 cells were transfected with annealing buffer alone, control siRNA, or E6 siRNA (Sp-18E6, Ex-18E6) twice, and then plated in a 96-well plate at a density of 750 cells/well. At 5 days after the first transfection, the number of relative viable cells was determined using a colorimetric assay. Sp-18E6 siRNA and Ex-18E6 siRNA were found to inhibit cell growth of HeLa cells to 1 and 22%, respectively, as compared with those transfected with buffer alone (Figure 4a) . Similarly, but to a lesser extent, Sp-18E6 siRNA and Ex-18E6 siRNA inhibited the growth of SW756 cells to 10 and 30%, respectively (Figure 4b ). The effects of the siRNAs on anchorage-independent growth of HeLa and SW756 cells were examined in soft agar cultures. Sp-18E6 siRNA and Ex-18E6 siRNA decreased the number of HeLa cell colonies formed in soft agar to 13 and 40%, respectively, as compared with buffer alone, whereas control siRNA showed no growth inhibition (107%) (Figure 4c) . Further, the suppression of anchorage-independent growth by Sp-18E6 and Ex-18E6 was more prominent in SW756 cells than in HeLa cells (Figure 4d) .
During the course of the monolayer growth experiment, morphological changes were observed in E6 siRNAtreated cells. At 3 days after siRNA transfection, E6 siRNA-treated cells began to shrink, which was followed by cell detachment and viability loss (data not shown). To assess the rate of cell death, annexin V binding and propidium iodide permeability were examined by flow cytometry. As shown in Figure 5 , Sp-E6 siRNA and Ex-18E6 siRNA transfection increased the population of annexin V-positive cells from 26 to 68% and to 55% in HeLa cells, respectively, whereas control siRNA had no such effect (22%). Most of the annexin V-positive cells were also positive for propidium iodide. These results showed that E6 siRNA caused cell death in HPV18-related cancer cells.
Discussion siRNAs are capable of nucleic acid sequence-based gene silencing, and have been used as a powerful tool in functional genomics. This technology is potentially applicable to drug targeting for genes involved in the pathogenesis of human diseases. For example, siRNAs against Fas and TNFa have been reported to control fulminant hepatitis 23, 24 and septic shock in mice, 25 respectively, while others have been reported to successfully inhibit replication of hepatitis B virus, 26,27 hepatitis C virus, 28, 29 and human immunodeficiency virus type 1. 30, 31 The application of an siRNA to cancer therapy appears to be more complicated, as recent molecular analyses have revealed that most oncogenes involved in carcinogenesis have no or only subtle sequence changes, such as point mutations and translocation. Thus, the ability to design siRNA specific to the target gene without siRNA designed to specifically target HPV18 E6 K Yamato et al disturbing the expression of the normal allele is a first problem to overcome. The primary cause of cervical cancer is expression of the E6 and E7 oncogenes of HPV16 and 18, which have no sequence homology to human genes. Therefore, designing E6 and E7 siRNAs with minimal off-target effect should be possible. Two reports, including ours, have demonstrated that the suppression of E6 and E7 expression by siRNA inhibited cellular growth of HPV16-positive cervical cancer cells. 13, 14 In the case of HPV18, an E6E7-specific siRNA, which downregulated both E6-E7 mRNA and E6*I-E7 mRNA, was reported to inhibit DNA synthesis and induce cellular senescence. 18 On the other hand, E6 monospecific siRNAs, specifically targeting E6-E7 mRNA but not E6*I-E7 mRNA, induced apoptosis in HeLa cells. 17 However, those reports do not include the detailed effects of siRNAs on the growth and viability of other HPV18-positive cancer cells.
It is known that these two HPV oncoproteins play different roles in the process of carcinogenesis and that their cooperation is essential for malignant transformation. 4 ,5 E7 primarily induces transformation, whereas E6 is responsible for cancer progression in vivo.
32,33 E7 directly binds to and inactivates a number of cell cycle regulatory proteins, including the 'pocket protein' family of Rb, 34, 35 thereby upregulating genes required for G1/S transition and DNA synthesis. In response to abnormal proliferation driven by E7, the host cells are induced to express proapoptotic genes, such as c-Myc, Bak, and p53. 36 However, in HPV-positive cancer cells, concomitantly expressed E6 rescues the cells from cell death by binding these proteins for degradation. 37, 38 It might be preferable to kill tumor cells, rather than just arrest cell growth, using RNAi as a treatment of cervical cancer. In that case, E6 would be the primary target for the development of a novel cervical cancer therapy with RNAi. For clinical application, it is also necessary to identify the target sequences of HPV siRNA that have potent and specific RNAi activities. We chose a target sequence of siRNA from E6 genes that efficiently silenced E6 and had minimal effect on E7 expression, and compared its antitumor cell activity with an siRNA that silenced both E6 and E7. It is known that mRNA coding E6 and E7 is transcribed from the same promoter in the form of a bicistronic transcript, with a number of alternative splicing variants designated as E6*I-IV encoding E6*I proteins, which are truncated forms of E6. [39] [40] [41] Importantly, E7 is equally and efficiently translated from E6-E7 and E6*I-E7 transcripts. 42 One siRNA, Ex-18E6, was selected within the common region of E6-E7 and E6*I-E7 mRNA so that it recognized and destructed both E6-E7 and E6*I-E7 mRNA, thereby knocking down both E6 and E7 (E6E7-specific siRNA). The other siRNA, Sp-18E6, contained the borderline sequence of the E6* splice donor site and its intron, and therefore, specifically destructed E6-E7 mRNA and left E6*I-E7 mRNA intact (E6 monospecific siRNA). In a cotransfection experiment, Sp-18E6 siRNA decreased the level of E6 but not the level of E6*I, whereas Ex-18E6 siRNA moderately decreased the levels of both E6 and E6*I. The effects of these E6 siRNAs on endogenous E6 and E7 were also examined with HeLa and SW756 cells. As expected, each E6 siRNA nearly completely destructed mRNA coding E6, while the reduction of mRNA coding E7 by Sp-18E6 was less efficient than by Ex-18E6, which was consistent with the effects of these siRNA on transiently expressed E6 and E6*I.
We also assessed the effects of siRNA on endogenous E6 protein expression by evaluating the level of p53, which is one of the most important targets of E6 degraded by the E6AP-mediated ubiquitin-proteasome pathway. 21, 22 Even though Sp-18E6 siRNA and Ex-18E6 had comparable RNAi activities towards mRNA coding E6, we found that effects of these siRNAs on p53 level were different: Sp-16E6 siRNA increased p53 to higher levels than Ex-18E6 siRNA, which was reciprocal to the levels of E7. These findings suggest that selective suppression of E6 might increase p53 to a higher level than suppression of both E6 and E7 in HPV18-positive cells. 43 Next, we examined the effects of two E6 siRNAs on the growth of HPV18-positive cancer cells in monolayer and siRNA designed to specifically target HPV18 E6 K Yamato et al soft agar cultures. Both showed moderate to strong suppression of monolayer and anchorage-independent growth of these cells, which was in part attributed to the induction of cell death. Sp-18E6 siRNA demonstrated more potent cell death-inducing activities than Ex-18E6 siRNA toward these cancer cells. The difference in antitumor cell activity between these siRNAs might have been caused by their different RNAi activities toward E7 expression. Further, it is conceivable that E7 expression without E6 coexpression could induce cell death by activating proapoptotic genes. When an effective delivery system for siRNAs becomes established, we believe that HPV-caused cervical cancer can be treated by an E6-targeting siRNA. E6 and E7 viral proteins, the culprits in cancer development, are indispensable for maintaining cancer phenotypes by, in part, inactivating cellular wild-type p53 and Rb. Thus, knockdown of the viral proteins should initiate the process of senescence, growth arrest, or apoptosis in tumor cells. From our results, selective E6 silencing might be a superior therapeutic strategy to silencing both E6 and E7, since expression of E7 alone might activate genes involved in the induction of growth suppression and apoptosis. To clarify this hypothesis, further experiments are being undertaken in our laboratories. It is also essential to determine the E6 target sequences of siRNA that show the strongest RNAi activity toward cancer cells, before such strategies can be applied clinically.
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